ArticleFrontiers in oncology2025
Prevalence of skin cancers in kidney transplant recipients - one-center experience.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-melanoma skin cancers (NMSCs) are the most common neoplasms that occur in solid organ transplant recipients (SOTRs). Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) make up over 90% of skin cancers in SOTRs. Key risk factors include age at transplantation, skin type, immunosuppression, as well as sun exposure (ultraviolet radiation) and viral infections, contributing significantly to tumor development. This study aimed to estimate the incidence and risk of NMSCs in kidney transplant recipients (KTRs) in Poland and to provide new clinical data on patients developing skin cancers in this population. Methods: This study included 105 KTRs, out of approximately 1,500, who were under the care of the Transplant Outpatient Clinic at the University Hospital in Gdansk between 1980 and 2022 and were diagnosed with NMSC. Results: A total of 250 cutaneous malignancies were diagnosed in 105 KTRs. BCC (58.8%) and SCC (37.6%) were the most common histological types, and the SCC: BCC ratio was approximately 2:3. Other skin neoplasms, including malignant melanoma (2%) or hidradenocarcinoma, were significantly less frequent. The mean age of KTRs at the time of skin cancer diagnosis was 59.6 years, with a mean time from transplantation to cancer diagnosis of 103.2 months. Most skin cancers were diagnosed 5-10 years post-transplantation and were located on the.24%). The immunosuppressive therapy protocol did not significantly affect the risk of developing skin cancer. The only significant factor associated with an increased risk of skin cancer was patient age. One patient died due to metastatic SCC. Conclusion: NMSCs account for 90% of skin cancers in KTRs; they have a high recurrence rate and are most often found on the face of older patients towards the end of the first decade after transplantation. Our study confirms that the risk of further skin neoplasm is high and that SCC can be a cause of death. Early detection not only improves prognosis but also minimizes the extent of surgical interventions, which is particularly crucial for lesions in visible areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.